Event-Driven Stocks

Solventum Corp

SOLVNYSE

Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs4 good1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22
Revenue$8.32B$8.25B$8.20B$8.13B
Operating income$2.18B$1.04B$1.69B$1.69B
Net income$1.56B$479.0M$1.35B$1.34B
Total assets$14.29B$14.46B$13.94B
Total liabilities$9.24B$11.50B$2.28B
Equity$5.05B$2.96B$11.67B$11.74B
EPS (diluted)$8.88$2.76$7.79$7.78
Shares out.173.0M00172.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
26.2%
Net margin
18.7%
Return on equity
30.8%
Return on assets
10.9%
Return on capital (ROCE)
19.5%
Liabilities / assets
64.7%
Debt / equity
1.83×
Book value / share
$29.19
Revenue growth (YoY)
0.9%
Net income growth (YoY)
224.8%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
2.34grey zone
Accruals / assets
8.3%moderate
Piotroski F-Score
7/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
70
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 warning4 good
  • Altman Z″ in the grey zone
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Positive operating cash flow

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • SOLUPREP SAug 8, 2018
  • DURAPREPSep 29, 2006
  • AVAGARDJun 7, 2001
  • PERIDEXAug 13, 1986

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20267.9M4.1+21.7%
Apr 30, 20266.5M6.4+1.6%
Apr 15, 20266.4M5.0+18.6%
Mar 31, 20265.4M3.5+35.7%
Mar 13, 20264.0M2.9+13.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spun off from 3M CompanyMMM · Mar 26, 2024

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (1)